Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.

Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.

Zhitong FinanceApr 25 17:30

Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.

BenzingaApr 25 17:29

PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101) IN PARTNERSHIP WITH PNOC SCIENTIFIC CONSORTIUM AND DAY ONE BIOPHARMACEUTICALS

The Pediatric Neuro-Oncology Consortium Foundation (PNOC Foundation), a platinum rated non-profit dedicated to supporting advancements in childhood...

PR NewswireApr 25 03:16

Day One Slips Despite Ojemda Approval as BofA Says Label "not a Home Run"

Seeking AlphaApr 25 03:05

Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher

TipRanksApr 24 20:13

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)

TipRanksApr 24 18:21